Picó Antonio, Aranda-López Ignacio, Sesmilo Gemma, Toldos-González Óscar, Japón Miguel A, Luque Raúl M, Puig-Domingo Manel
Servicio de Endocrinología y Nutrición, Instituto de Investigación Sanitaria y Biomédica de Alicante-Hospital General Universitario de Alicante, Universidad Miguel Hernández, Alicante, España.
Servicio de Anatomía Patológica, Hospital General Universitario de Alicante/ISABIAL, Alicante, España.
Rev Esp Patol. 2021 Oct-Dec;54(4):263-274. doi: 10.1016/j.patol.2020.11.006. Epub 2021 Mar 1.
Pituitary neuroendocrine tumors (PitNETs) constitute, together with other tumors of the sellar region, 15-25% of intracranial neoplasms. In 2017, the World Health Organization proposed a new classification of PitNETs. The main innovation with respect to the 2004 classification was the recommendation to include in the immunohistochemical evaluation of PitNETs the determination of the transcription factors of the 3 pituitary cell lineages: Pit-1, Tpit and SF-1. Additionally, other clinicopathological classifications with a predictive capacity of tumor behavior during follow-up were proposed. Given these changes, it is appropriate to adapt the knowledge generated during the last 15 years to the daily practice of the treatment and monitoring of PitNETs at the Centers of Excellence in Pituitary Pathology. This document includes the positioning of the Spanish Society of Endocrinology and Nutrition (SEEN) and the Spanish Society of Pathology (SEAP) on the classification and denomination of the PitNETs and the information that the pathologist should provide to the clinician to facilitate the treatment and monitoring of these tumors.
垂体神经内分泌肿瘤（PitNETs）与鞍区的其他肿瘤一起，占颅内肿瘤的15%-25%。2017年，世界卫生组织提出了PitNETs的新分类。与2004年分类相比，主要创新之处在于建议在PitNETs的免疫组织化学评估中纳入对3种垂体细胞谱系转录因子的测定：Pit-1、Tpit和SF-1。此外，还提出了其他具有预测随访期间肿瘤行为能力的临床病理分类。鉴于这些变化，有必要将过去15年中产生的知识应用于垂体病理学卓越中心对PitNETs的治疗和监测的日常实践中。本文档包括西班牙内分泌与营养学会（SEEN）和西班牙病理学会（SEAP）对PitNETs的分类和命名的立场，以及病理学家应向临床医生提供的信息，以促进对这些肿瘤的治疗和监测。
